Therefore, the current Children’s Oncology Group (COG) phase 3 clinical trial for AML risk-stratifies patients with FLT3-ITD allelic ratios >0.4 into the high-risk group, regardless of having any other low risk factor. This evidence concerns the gene FLT3 and acute myeloid leukemia.